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Abstract
Background: The emergence of multidrug-resistant strains is a major health problem especially for countries with
high TB incidence such as Peru. In this study, we evaluated High Resolution Melting (HRM) assay in Peruvian isolates
for the detection of mutations within rpoB, katG genes and promoter region inhA to determine isoniazid and rifampicin
resistance in Mycobacterium tuberculosis (Mtb).
Methods: DNA samples extracted from a total of 167 clinical isolates of Mtb, 89 drug-sensitive and 78 multidrug-resistant,
were blindly analyzed by HRM analysis and verified by DNA sequencing.
Results: The HRM analysis generated patterns that were specific to distinguish between sensitive and resistance isolates.
The sensitivity and specificity of the HRM assays in comparison with drug susceptibility testing (DST) for detection of
rifampicin resistance were 98.7 % and 97.5 %, and for isoniazid resistance were 98.7 % and 100 %.
Conclusion: This study suggests that HRM Analysis could help with rapid diagnosis of MDR-TB cases in Peru.
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Background
In countries with high TB burden such as Peru, the emer-
gence of multidrug-resistant strains is a major health prob-
lem. In 2013, Peru registered 27 504 new TB cases (21 916
pulmonary and 5588 extrapulmonary), from which a 3.9 %
(850) were multidrug-resistant tuberculosis (MDR-TB) [1].
MDR-TB is defined as resistance to rifampicin and isonia-
zid, two of the first-line anti-TB drugs [1]. According to
the WHO TB report, research should focus on the devel-
opment of simple and rapid diagnostic methods that can
be used at first level health facilities to diagnose and thus
prevent the increase of MDR-TB cases [2]. The conven-
tional phenotypic drug susceptibility testing (DST) method,
Agar Proportion Method (APM) continues to be the gold
standard for Mtb DST. The problem with the current
conventional DST methods available is that they are gener-
ally carried out after a culture is isolated from a clinical
sample detecting Mtb’s growth in the presence of anti-TB
drugs by absolute concentration, resistance ratio or portion
methods on solid medium having a turnaround time of
about 2–4 weeks. Therefore, more rapid TB DST methods
that can use clinical samples directly are needed to give a
prompt diagnosis. Some non-commercially available direct
methods such as MODS (microscopic observation drug
susceptibility) assay have been developed. However, the
MODS assay, which can process a large number of sputum
samples with results in 7–9 days, is too laborious and time
consuming due to the need of daily plate readings [3].
There has been an increased effort to develop new simple
and rapid diagnostic molecular methods for MDR-TB
taking advantage of mutations that render resistance [4].
For rifampicin, resistance is observed with the presence of
localized mutations in the 81 bp region of the rpoB gene
[5]. Also, mutations in the rpoA and rpoC regions have
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been recently reported in resistant strains and would be
important in future diagnostic methods [6, 7]. Resistance to
isoniazid is observed mostly with the presence of mutations
in katG. Other important mutations also occur in ahpC,
kasA, ndh genes and the promoter region of inhA [8–11].
The current molecular methods can detect resistance-
associated mutations within 1–2 days using clinical sam-
ples. One of the commercially available molecular methods
is Xpert MTB/RIF (Cepheid), a real-time PCR assay that
detects rifampicin resistance in sputum samples. There are
also two commercially available DNA macroarray assays
(reverse hibridization-based line probe assays), INNO-LiPA
rif (Innogenetics), which detect mutations on rpoB gene,
and MTBDRplus (Hain Lifesciences), which simultaneously
detects rifampicin (rpoB gene) and isonizid (katG and inhA
region) resistance [12, 13]. These assays are able to reduce
the time for MDR-TB diagnosis. In our quest to develop
another molecular method that can be helpful for diagnos-
ing MDR-TB and be implemented in Peru, we evaluated
the HRM assay. Some of the advantages of HRM analysis
include short processing time, simple procedure and low
cost compared to current methods used in Peru [14]. HRM
is based on the analysis of fluorescence curves produced by
DNA intercalating dye during strand dissociation events in
the melting phase following real-time PCR. It allows the
detection of genetic mutations or variance in nucleic acid
sequences [15]. The use of this methodology include identi-
fication of SNPs, genotyping, gene scanning, sequence
matching and nucleic acids methylation [16]. In this study,
we evaluated the detection of mutations in rpoB, katG
genes and the inhA promoter region by HRM analysis
using Peruvian culture isolates with known phenotypic sus-
ceptibility profiles of MDR-TB.
Methods
Sample collection
DNA samples extracted from a total of 167 Mtb isolates
were used for this study. Convenience sampling was ap-
plied. The isolates were provided by the Laboratory Refer-
ence of Mycobacteria from DIRESA Callao, province with
one of the highest number of TB cases in PERU. 89 isolates
had sensitive phenotype (susceptible to both rifampicin
and isoniazid) and 78 isolates had multidrug-resistant
phenotype (resistant to both rifampicin and isoniazid), as
determined by MODS. MODS assay was performed as
described previously [17, 18] using critical concentrations
of 0.4 μg/mL for isoniazid and 1.0 μg/mL for rifampicin.
All but 14 isolates that had a resistant phenotype were
verified by APM in the Reference Laboratory of Mycobac-
teria at the Instituto Nacional de Salud. Briefly, APM was
performed in accordance with WHO guidelines [19] on
Middlebrooks 7H10 agar containing 0.2 μg.ml and 1 μg/ml
for INH or 1 μg/ml for RIF. The MODS and APM results
were concordant in all samples analyzed. 64 % of the
resistant samples had high level INH resistance and 11.5 %
had low-level INH resistance. 17.9 % of the resistant sam-
ples had no APM results available (some due to their
inability to grow on agar. For those, a molecular testing
method was done). All the isolates that had the high level
INH resistance and only one had both katG and inhA
mutations, had katG mutations, and all the isolates that
had low level INH resistance had inhA mutations.
All other processes and experimental methodologies were
performed in the Biotechnology and Molecular Biology
Laboratory at the Instituto Nacional de Salud (INS), Chor-
rillos. This project was approved by the INS‘s Research and
Ethical Committees (OI-017-13) and has the participants’
consent to publish these data.
Extraction of DNA
Bacteria, grown on Lowenstein Jensen solid medium,
were resuspended in molecular biology grade water and
sonicated using S2 ultrasonicator (Covaris Inc, USA).
The bacterial solution was then treated with lysozyme over-
night. Finally, the DNA was extracted using the PureLink™
Genomic DNA kit (ThermoFisher Scientific, USA) accord-
ing to manufacturer’s procedure.
High resolution melting analysis
HRM assays were performed using Type I HRM PCR kit
(Qiagen). All samples were tested in duplicates. The primers
used for these experiments were previously reported [20]
(Table 1). For confirmation ofMtb, the IS6110 primers were
used. Each reaction included: 1X HRM master mix (con-
taining HotStarTaq Plus DNA polymerase, HRM PCR
buffer with EvaGreen dye, Q-solution and dNTPs), 0.7uM
of each primer, 2 ul (1 ng/ul) of Mtb DNA, and RNase-Free
water. All assays were run on the Rotor-Gene Q real time
Table 1 Sequences of the primers used HRM analysis



















F forward primer; R reverse primer
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PCR instrument (Qiagen, USA) using the following cycling
parameters: initial denaturation at 95 °C for 10 min, 45 cycles
of 94 °C for 30 s and 60 °C for 40 s. For HRM analysis, a
second hold was set at 60 °C for 1 min to allow reannealing
of the amplified DNA. The melt analysis was performed
from 80–94 °C with 0.1 °C increments every 2 s. The refer-
ence strain H37Rv, susceptible to RIF and INH, was in-
cluded in each run as a wild-type positive control and
nuclease free water was used as a negative control. The biol-
ogists who performed the HRM analysis were blinded to the
phenotype and genotype resistance data.
The HRM data were analyzed with the Rotor-Gene Q
software. The melting curves generated represented by dif-
ferent color lines and shapes easily differentiate between
sensitive and resistant isolates.
DNA sequencing
Sequencing analysis was used to confirm resistance in all
phenotypically resistant strains using the primers listed
on Table 2, which have been previously reported (16).
Sequencing was performed using 3500 Genetic Analyzer
(Applied Biosystems, USA), and subsequent alignment
was done using Geneious 5.4.4 program.
Statistical analysis
The sensitivity and specificity parameters were calculated
before and after discrepancies were resolved using statistical
formula. Sensitivity was calculated as follows: (true positive/
(true positive + false negative); specificity was calculated as
follows: (true negative)/(true negative + false positive). The
data were analyzed using the EPIDAT ver. 3.1 software. The
study conforms to the international standards for reporting
of diagnostic accuracy (STARD) requirements [21].
Results and Discussion
Detection of rifampicin resistance using HRM analysis
To evaluate the ability of the HRM assay to detect rifampi-
cin resistance, we analyzed sequence variations in a 118 bp
region of the rpoB gene on the DNA samples of 167 Mtb
isolates. 89 isolates were sensitive and 78 were MDR as
determined by MODS and confirmed by APM. According
to the HRM results, there were phenotypic and genotypic
(HRM analysis) concordance for 77 out of 78 resistant iso-
lates. One phenotypic resistant isolate was genotypic sensi-
tive and two phenotypic sensitive isolates were genotypic
resistant by HRM (Fig. 1).
Table 2 Sequence of primers used DNA sequencing











F forward; R reverse
rpoB
Fig. 1 HRM curve analysis for resistant discrimination in 118 bp amplified fragment from rpoB gene. Resistant profiles with positive and negative
fluorescence are shows in red circles (five samples). Sensitive profiles are shows in black circle (seven samples)
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Detection of isoniazid resistance using HRM analysis
To evaluate the ability of the HRM assay to detect isoniazid
resistance, we analyzed sequence variations in a 235 bp
region of the katG gene and in a 190 bp region of the inhA
promoter the DNA samples of the 167 isolates. The results
of the HRM analysis showed that there was phenotypic and
genotypic (HRM analysis) concordance for 77 out of 78
resistant isolates. One phenotypic resistant isolate was
genotypic sensitive. HRM analysis for katG gene detected
90 sensitive and 67 isoniazid resistant isolates (Fig. 2), and
for the promoter region of inhA 90 sensitive and 10 isonia-
zid resistant isolates were detected (Fig. 3).
DNA sequencing
Seventy-eight samples with drug-resistant profiles were
sequenced for the rpoB, katG and inhA targets (Table 3).
Fourteen types of mutations were observed in the rpoB
gene of the resistant samples, with S531L (TCG➔TTG)
katG
Fig. 2 HRM curve analysis for resistant discrimination in 235 pb amplified fragment from katG gene. Resistant profiles are show in red circle (four samples).
Sensitive profiles are show in black circle (eight samples)
inhA
Fig. 3 HRM curve analysis for resistant discrimination in 190 pb amplified fragment from inhA promotor region. Resistant profiles are show in red
circle (seven samples). Sensitive profiles are show in black circle (ten samples)
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being the most common. In the katG gene, the most com-
mon mutation was S315T, and C→T (−15) for inhA pro-
moter. All the mutations observed have been previously
linked to resistance to INH and RIF.
Two samples with a sensitive phenotype that turn out
resistant by HRM analysis were also sequenced. Sequen-
cing revealed a synonymous mutation in codon 514
(TTC➔TTT), reason why the sample has a sensitive
phenotype. A drug-resistant sample that gave wild-type
results with HRM analysis had no mutations in rpoB, katG
and inhA promoter, suggesting the possibility of mutations
in other genes (like rpoA, rpoC, ahpC, kasA and ndh).
Analysis of sensitivity and specificity of HRM analysis
Most of HRM analysis results were consistent with the
resistant or sensitive phenotype. The sensitivity for detec-
tion of rifampicin resistance was found to be 98.7 % and
the specificity 97.75 %. For isoniazid resistance (katG and/
or inhA), the sensitivity was found to be 98.7 % and the
specificity 100 % (Table 4).
Conclusions
At present, a rapid and effective diagnosis for TB and
MDR-TB is necessary to provide a better treatment for
infected individuals. Molecular biology techniques like
HRM analysis can be employed to detect MDR-TB due to
their high sensitivity, specificity and efficiency [20, 22, 23].
In this study, we evaluated the performance of HRM
curve analysis as a method for the rapid and accurate
detection of mutations associated to MDR-TB. All isolates
with drug-resistance profiles were confirmed by DNA se-
quencing analysis. In comparison with previous studies,
our results of sensitivity and specificity are similar to
others (24–26). One limitation of the current study is that
the target region used for the HRM analysis does not
cover all mutations related to resistance, and thus, the
technique cannot yet replace conventional DST. Another
Table 3 Results of HRM curves analysis for rpoB, katG and inhA targets in Mycobacterium tuberculosis
DRUG PHENOTYPE TARGET N° MUTATION HRM CURVE ASSAY DNA SEQUENCING
RIFAMPICIN Resistant (78) rpoB 53 S531L (TCG→ TTG) mutant mutant
14 D516V (GAC→ GTC) mutant mutant
2 H526D (CAC→ GAC) mutant mutant
1 Q513L (CAA→ CTA) mutant mutant
1 Q513P (CAA→ CCA) mutant mutant
1 M515I (ATG→ ATA), D516G (GAC→ GGC) mutant mutant
1 D516Y (GAC→ TAC), N518H (AAC→ CAC) mutant mutant
1 H526R (CAC→ CGC) mutant mutant
1 H526Y (CAC→ TAC) mutant mutant
1 S531F (TCG→ TTT) mutant mutant
1 S531W (TCG→ TGG) mutant mutant
1 No mutation wild wild
Susceptible (89) 87 Not sequenced wild -
2 514 Phe (TTC→ TTT) mutant wild
ISONIAZID Resistant (78) katG 66 S315T (AGC→ ACC) mutant mutant
1 S315T (AGC→ ACC), C→ T (−15) mutant mutant
inhA 10 C→ T (−15) mutant mutant
katG,inhA 1 No mutation wild wild
Susceptible (89) 87 Not sequenced wild -
2 No mutation wild wild
Table 4 Sensitivity and specificity of HRM analysis in comparison with Drug susceptibility




Sensitivity (%) Specificity (%)
+ − + −
Rifampicin rpoB 79 88 47.3 78 89 46.7 98.7 (92.2–99.9) 97.75 (91.2–99.6)
Isoniazid katG and/or 77 90 46.1 78 89 46.7 98.7 (92.2–99.9) 100 (94.2–99.9)
inhA promoter
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limitation is that the test may detect silent or other muta-
tions not actually associated with drug resistance. An ad-
vantage of this technique is that it can be implemented to
detect fluoroquinolone, pyrazinamide and streptomycin
resistance [24–26].
In conclusion, this study showed that using the rpoB,
katG genes and inhA promoter region as targets in the
HRM assay can be used to detect MDR-TB in culture
isolates with high sensibility and specificity. Evaluation
of the HRM assay on sputum samples would be an im-
portant next step to further expedite MDR-TB detection.
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